Literature DB >> 2747516

Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites.

J Frahm1, H Bruhn, M L Gyngell, K D Merboldt, W Hänicke, R Sauter.   

Abstract

High-resolution proton NMR spectra of normal human brain in vivo have been obtained from selected 27- and 64-ml volumes-of-interest (VOI) localized in the insular area, the occipital area, the thalamus, and the cerebellum of normal volunteers. Localization was achieved by stimulated echo (STEAM) sequences using a conventional 1.5-T whole-body MRI system (Siemens Magnetom). The proton NMR spectra show resonances from lipids, lactate, acetate, N-acetylaspartate (NAA), gamma-aminobutyrate, glutamine, glutamate, aspartate, creatine and phosphocreatine, choline-containing compounds, taurine, and inositols. While T1 relaxation times of most of these metabolites were about 1100-1700 ms without significant regional differences, their T2 relaxation times varied between 100 and 500 ms. The longest T2 values of about (500 +/- 50) ms were observed for the methyl protons of NAA in the white matter of the occipital lobe compared to (320 +/- 30) ms in the other parts of the brain. No significant regional T2 differences were found for choline and creatine methyl resonances. The relative concentrations of NAA in gray and white matter were found to be 35% higher than those in the thalamus and cerebellum. Assuming a concentration of 10 mM for total creatine the resulting NAA concentrations of 13-18 mM are by a factor of 2-3 higher than previously reported using analytical techniques. Cerebral lactate reached a maximum concentration of about 1.0 mM.

Entities:  

Mesh:

Year:  1989        PMID: 2747516     DOI: 10.1002/mrm.1910110105

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  65 in total

1.  Multivoxel 3D proton spectroscopy in the brain at 1.5 versus 3.0 T: signal-to-noise ratio and resolution comparison.

Authors:  O Gonen; S Gruber; B S Li; V Mlynárik; E Moser
Journal:  AJNR Am J Neuroradiol       Date:  2001-10       Impact factor: 3.825

2.  Decreasing choline signal--a marker of phenylketonuria?

Authors:  M Dezortová; L Hejcmanová; M Hájek
Journal:  MAGMA       Date:  1996 Sep-Dec       Impact factor: 2.310

Review 3.  [(1)H magnetic resonance spectroscopy (MRS) of the liver and hepatic malignant tumors at 3.0 Tesla].

Authors:  F Fischbach; M Thormann; J Ricke
Journal:  Radiologe       Date:  2004-12       Impact factor: 0.635

Review 4.  NMR studies of drug metabolism and disposition.

Authors:  J D Bell; D G Gadian; N E Preece
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

5.  (1)H-MRS of brain metabolites in migraine without aura: absolute quantification using the phantom replacement technique.

Authors:  Harmen Reyngoudt; Yves De Deene; Benedicte Descamps; Koen Paemeleire; Eric Achten
Journal:  MAGMA       Date:  2010-08-13       Impact factor: 2.310

6.  Prognostic significance of metabolic changes detected by proton magnetic resonance spectroscopy in ischaemic stroke.

Authors:  F Federico; I L Simone; C Conte; V Lucivero; P Giannini; M Liguori; E Picciola; C Tortorella
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

Review 7.  Proton MR spectroscopy of the brain at 3 T: an update.

Authors:  Alfonso Di Costanzo; Francesca Trojsi; Michela Tosetti; Timo Schirmer; Silke M Lechner; Teresa Popolizio; Tommaso Scarabino
Journal:  Eur Radiol       Date:  2007-01-18       Impact factor: 5.315

Review 8.  Recent advances in magnetic resonance neurospectroscopy.

Authors:  Yael Rosen; Robert E Lenkinski
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

9.  Proton magnetic resonance spectroscopy in patients with ischemic stroke.

Authors:  F Federico; C Conte; I L Simone; P Giannini; M Liguori; E Picciola; C Tortorella; E Ferrari
Journal:  Ital J Neurol Sci       Date:  1994-11

10.  Brain MR spectroscopic abnormalities in "MRI-negative" tuberous sclerosis complex patients.

Authors:  William E Wu; Ivan I Kirov; Assaf Tal; James S Babb; Sarah Milla; Joseph Oved; Howard L Weiner; Orrin Devinsky; Oded Gonen
Journal:  Epilepsy Behav       Date:  2013-03-22       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.